CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Tocilizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03726749
NCT03726749Phase 4Completed
CompareCT.gov

Tocilizumab Plus a Short Prednisone Taper for Giant Cell Arteritis (GCA)

Massachusetts General Hospital·interventional·Posted Oct 31, 2018·Updated Dec 2, 2022

In Brief

A Phase 4 clinical trial evaluating Tocilizumab and Prednisone for Giant Cell Arteritis. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGiant Cell Arteritis
CountriesUnited States
CollaboratorsRoche-Genentech

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 31, 2018
Enrollment StartNov 28, 2018
Primary CompletionDec 15, 2021
Study CompletionDec 29, 2021
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 7.7 years ago

Interventions

Tocilizumabdrug

Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor

Prednisonedrug

Prednisone is an anti-inflammatory medication